08Jun 2022
Botulinum toxin in patients at‐risk for bladder augmentation: Durable impact or kicking the can?

Botulinum toxin in patients at‐risk for bladder augmentation: Durable impact or kicking the can?

This article presents overall experience with BTX and its role in mitigating the “at‐risk” NGB, as determined by urodynamic characteristics. Post‐first BTX UDS demonstrated downgrading of risk group in 38% and 63% using NSBPR and LCH classifications, respectively. Encouraging improvements in the urodynamic risk group were noted in some patients. With careful counselling and follow‐up, BTX may safely extend the time to BA in some “at‐risk” patients.

  • #urology

Like

Save

Share